Allos Therapeutics Announces Presentations on EFAPROXYN(TM) and PDX at Upcoming Scientific Conferences
01 11월 2006 - 2:30AM
PR Newswire (US)
WESTMINSTER, Colo., Oct. 31 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (NASDAQ:ALTH) today announced that data
evaluating the Company's product candidates EFAPROXYN (efaproxiral)
and PDX (pralatrexate) have been accepted for presentation at the
following scientific conferences: * American Society for
Therapeutic Radiology and Oncology: Hak Choy, M.D., Chairman,
Department of Radiation Oncology, University of Texas Southwestern
Medical Center, is scheduled to present an updated survival
analysis of data from a Phase 2 trial of EFAPROXYN in patients with
locally advanced (Stage IIIA/B) non-small cell lung cancer in an
oral presentation titled "Comparison of 5-Year Survival Between
RTOG-94-10 and a Phase 2 Study of Induction Chemotherapy Followed
by Efaproxiral + Radiotherapy in Patients with Locally Advanced
NSCLC" on Monday, November 6. In addition, Huagang Hou, M.D.,
Research Assistant Professor of Radiology, Dartmouth Medical
School, is scheduled to report findings from a pre-clinical study
of EFAPROXYN in a slide presentation titled "Effects of repeated
EFAPROXYN (TM) (efaproxiral) dosing, an allosteric hemoglobin
modifier, on oxygenation and enhancement of radiotherapy in
subcutaneous RIF-1 tumors, in mice" on Tuesday, November 7. *
EORTC-NCI-AACR International Conference on Molecular Targets and
Cancer Therapeutics: Owen O'Connor, M.D., Ph.D., Head of the
Laboratory of Experimental Therapeutics for Lymphoproliferative
Malignancies, Lymphoma and Development Chemotherapy Services,
Memorial Sloan-Kettering Cancer Center, is scheduled to present
updated data from an on-going Phase 1/2 study of PDX in patients
with relapsed or refractory non-Hodgkin's lymphoma and Hodgkin's
disease in a poster presentation titled "Clinical Experience with
Pralatrexate (10-Propargyl-10-deazaaminopterin (PDX)), a Novel
Antifolate with High Affinity for the Reduced Folate Carrier, in
Patients with Chemotherapy Refractory Lymphoproliferative
Malignancies" on Friday, November 10. Copies of the posters will be
available on the Company's website, http://www.allos.com/, the day
following each presentation and will be archived for 30 days. About
Allos Therapeutics, Inc. Allos Therapeutics, Inc. (ALTH) is a
biopharmaceutical company focused on the development and
commercialization of small molecule therapeutics for the treatment
of cancer. The Company has two product candidates in late-stage
clinical development: EFAPROXYN (efaproxiral), a radiation
sensitizer currently under evaluation in a pivotal Phase 3 trial in
women with brain metastases originating from breast cancer, and PDX
(pralatrexate), a novel, next generation antifolate currently under
evaluation in a pivotal Phase 2 trial in patients with relapsed or
refractory peripheral T-cell lymphoma. The Company is also
evaluating RH1, a targeted chemotherapeutic agent, in a Phase 1
trial in patients with advanced solid tumors. For additional
information, please visit the Company's website at
http://www.allos.com/. Safe Harbor Statement The anticipated
presentations will contain forward-looking statements that involve
significant risks and uncertainties, including those to be
discussed in the presentation and others that can be found in the
"Risk Factors" section of the Company's Form 10-K for the year
ended December 31, 2005 and in the Company's periodic reports on
Form 10-Q and Form 8-K. The Company does not undertake any
obligation to update any forward-looking statements contained in
the anticipated presentation as a result of new information, future
events or otherwise. The Company cautions investors not to place
undue reliance on the forward-looking statements contained in the
presentation. No forward-looking statement can be guaranteed and
actual events and results may differ materially from those
projected. DATASOURCE: Allos Therapeutics, Inc. CONTACT: Jennifer
Neiman Manager, Corporate Communications of Allos Therapeutics,
+1-720-540-5227, Web site: http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More Allos Therapeutics (MM) News Articles